Cancer incidence and mortality in France over the 1980???2012 period: Solid tumors, Revue d'??pid??miologie et de Sant?? Publique, vol.62, issue.2, pp.95-108, 2014. ,
DOI : 10.1016/j.respe.2013.11.073
Epidemiologic Aspects of Renal Cell Carcinoma, Seminars in Oncology, vol.33, issue.5, pp.527-560, 2006. ,
DOI : 10.1053/j.seminoncol.2006.06.010
Current Pathology Keys of Renal Cell Carcinoma, European Urology, vol.60, issue.4, pp.634-677, 2011. ,
DOI : 10.1016/j.eururo.2011.06.047
Imaging features, follow-up, and management of incidentally detected renal lesions, Clinical Radiology, vol.66, issue.12, pp.1129-1168, 2011. ,
DOI : 10.1016/j.crad.2011.07.044
Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome, Journal of Clinical Oncology, vol.34, issue.18, pp.2172-81, 2016. ,
DOI : 10.1200/JCO.2015.65.6140
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer, Clinical Cancer Research, vol.10, issue.18, pp.6290-6295, 2004. ,
DOI : 10.1158/1078-0432.CCR-sup-040025
Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia, Cancer Res. 1 avr, vol.61, issue.7, pp.3206-3217, 2001. ,
Angiogenic factors, Science, vol.235, issue.4787, pp.442-449, 1987. ,
DOI : 10.1126/science.2432664
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, The Lancet, vol.370, issue.9605, pp.2103-2114, 2007. ,
DOI : 10.1016/S0140-6736(07)61904-7
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206, Journal of Clinical Oncology, vol.28, issue.13, pp.2137-2180, 2010. ,
DOI : 10.1200/JCO.2009.26.5561
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.115-139, 2007. ,
DOI : 10.1056/NEJMoa065044
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.369, issue.8, pp.722-753, 2013. ,
DOI : 10.1056/NEJMoa1303989
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007. ,
DOI : 10.1056/NEJMoa060655
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial, The Lancet Oncology, vol.14, issue.6, pp.552-62, 2013. ,
DOI : 10.1016/S1470-2045(13)70093-7
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1814-1837, 2015. ,
DOI : 10.1056/NEJMoa1510016
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial, The Lancet Oncology, vol.12, issue.7, pp.673-80, 2011. ,
DOI : 10.1016/S1470-2045(11)70124-3
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-56, 2008. ,
DOI : 10.1016/S0140-6736(08)61039-9
Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma, PLOS ONE, vol.373, issue.34, p.155389, 2016. ,
DOI : 10.1371/journal.pone.0155389.s004
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1816, 2015. ,
DOI : 10.1056/NEJMoa1510665
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie, Annals of Oncology, vol.13, issue.9, pp.1460-1468, 2002. ,
DOI : 10.1093/annonc/mdf257
Comparison of two major prognostic models for patients with metastatic renal cell carcinoma treated in the contemporary era of targeted therapies., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.2011 ,
DOI : 10.1200/jco.2011.29.15_suppl.4660
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor???Targeted Agents: Results From a Large, Multicenter Study, Journal of Clinical Oncology, vol.27, issue.34, pp.5794-5803, 2009. ,
DOI : 10.1200/JCO.2008.21.4809
Advances and controversies in grading and staging of renal cell carcinoma, Modern Pathology, vol.19, issue.2, pp.24-36, 2009. ,
DOI : 10.1309/0FT8WTDKREFHHP4P
Protein kinases. 4 Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation, FASEB J Off Publ Fed Am Soc Exp Biol. mars, vol.9, issue.5, pp.313-336, 1995. ,
The shape of things to come: An emerging role for protein kinase CK2 in the regulation of cell morphology and the cytoskeleton, Cellular Signalling, vol.18, issue.3, pp.267-75, 2006. ,
DOI : 10.1016/j.cellsig.2005.07.008
Crystal structure of the human protein kinase CK2 regulatory subunit reveals its zinc finger-mediated dimerization, The EMBO Journal, vol.18, issue.11, pp.2930-2970, 1999. ,
DOI : 10.1093/emboj/18.11.2930
Dynamic Localization/Association of Protein Kinase CK2 Subunits in Living Cells, Annals of the New York Academy of Sciences, vol.10, issue.1, pp.272-279, 2002. ,
DOI : 10.1111/j.1749-6632.2002.tb04648.x
Visualization and molecular analysis of nuclear import of protein kinase CK2 subunits in living cells, Mol Cell Biochem. nov, vol.227, issue.1?2, pp.81-90, 2001. ,
DOI : 10.1007/978-1-4615-1723-8_10
La prot??ine kinase CK2, une enzyme qui cultive la diff??rence, m??decine/sciences, vol.19, issue.6-7, pp.709-725, 2003. ,
DOI : 10.1051/medsci/20031967709
The Alpha Catalytic Subunit of Protein Kinase CK2 Is Required for Mouse Embryonic Development, Molecular and Cellular Biology, vol.28, issue.1, pp.131-140, 2008. ,
DOI : 10.1128/MCB.01119-07
Functional Polymorphism of the CK2?? Intronless Gene Plays Oncogenic Roles in Lung Cancer, PLoS ONE, vol.16, issue.7, p.11418, 2010. ,
DOI : 10.1371/journal.pone.0011418.s001
Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer, Eur J Cancer Oxf Engl mars, vol.43, issue.5, pp.928-962, 1990. ,
URL : https://hal.archives-ouvertes.fr/inserm-00413230
Protein Kinase CK2?? as an Unfavorable Prognostic Marker and Novel Therapeutic Target in Acute Myeloid Leukemia, Clinical Cancer Research, vol.13, issue.3, pp.1019-1047, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-1602
Protein kinase CK2?? subunit over-expression correlates with metastatic risk in breast carcinomas: Quantitative immunohistochemistry in tissue microarrays, European Journal of Cancer, vol.47, issue.5, pp.792-801, 1990. ,
DOI : 10.1016/j.ejca.2010.11.028
Intracellular Hydrogen Peroxide Production Is an Upstream Event in Apoptosis Induced by Down-Regulation of Casein Kinase 2 in Prostate Cancer Cells, Molecular Cancer Research, vol.4, issue.5, pp.331-339, 2006. ,
DOI : 10.1158/1541-7786.MCR-06-0073
Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction, Oncogene, vol.61, issue.11, pp.1373-83, 2013. ,
DOI : 10.1002/ijc.24177
Protein kinase CK2 in breast cancer: the CK2?? regulatory subunit takes center stage in epithelial plasticity, Cellular and Molecular Life Sciences, vol.8, issue.10, pp.3305-3327, 2015. ,
DOI : 10.1007/s00018-015-1929-8
Asymmetric Expression of Protein Kinase CK2 Subunits in Human Kidney Tumors, Biochemical and Biophysical Research Communications, vol.202, issue.1, pp.141-148, 1994. ,
DOI : 10.1006/bbrc.1994.1904
Antitumoral activity of allosteric inhibitors of Protein kinase CK2, Oncotarget, vol.2, issue.12, pp.997-1010, 2011. ,
DOI : 10.18632/oncotarget.361
A moncentric review of targeted therapy on overall survival in metastatic renal clear cell carcinoma, J Clin Oncol, vol.31, issue.15593, p.2013 ,
Amélioration de la survie globale des patients porteurs de cancer du rein métastatique gr?ace aux thérapies ciblées : revue monocentrique depuis, p.824923, 2000. ,
Grading of Clear Cell Renal Cell Carcinoma Should be Based on Nucleolar Prominence, The American Journal of Surgical Pathology, vol.35, issue.8, pp.1134-1143, 2011. ,
DOI : 10.1097/PAS.0b013e318220697f
PROGNOSTIC ROLE OF FUHRMAN GRADE AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN pT1a CLEAR CELL CARCINOMA IN PARTIAL NEPHRECTOMY SPECIMENS, The Journal of Urology, vol.174, issue.4, pp.1208-1220, 2005. ,
DOI : 10.1097/01.ju.0000173078.57871.2d
Prognostic Role of Tumor Necrosis, Microvessel Density, Vascular Endothelial Growth Factor and Hypoxia Inducible Factor-1?? in Patients with Clear Cell Renal Carcinoma after Radical Nephrectomy in a Long Term Follow-up, International Journal of Immunopathology and Pharmacology, vol.66, issue.2, pp.447-55, 2008. ,
DOI : 10.1097/00000478-198210000-00007
Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma, Oncology Letters ,
DOI : 10.3892/ol.2012.1001
Impact of an Altered Wnt1/??-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma, International Journal of Molecular Sciences, vol.14, issue.6, pp.10944-57, 2013. ,
DOI : 10.3390/ijms140610944
On the role of aurora-A in centrosome function, Oncogene, vol.21, issue.40, pp.6175-83, 2002. ,
DOI : 10.1038/sj.onc.1205775
URL : https://hal.archives-ouvertes.fr/inserm-00966247
Significance of Aurora-A expression in renal cell carcinoma, Urologic Oncology: Seminars and Original Investigations, vol.25, issue.2, pp.128-161, 2007. ,
DOI : 10.1016/j.urolonc.2006.06.001
Apicobasal polarity in the kidney, Experimental Cell Research, vol.318, issue.9, pp.1033-1042, 2012. ,
DOI : 10.1016/j.yexcr.2012.02.028
Overexpression of the polarity protein PAR-3 in clear cell renal cell carcinoma is associated with poor prognosis, International Journal of Cancer, vol.135, issue.9, pp.2051-60, 2014. ,
DOI : 10.1002/ijc.28548
URL : https://hal.archives-ouvertes.fr/hal-01010658
Cytoplasmic PAR-3 protein expression is associated with adverse prognostic factors in clear cell renal cell carcinoma and independently impacts survival, Human Pathology, vol.45, issue.8, pp.1639-1685, 2014. ,
DOI : 10.1016/j.humpath.2014.03.018
URL : https://hal.archives-ouvertes.fr/hal-01058621
Cell polarity protein CRB3 is an independent favorable prognostic factor for clear cell renal cell carcinoma, International Journal of Oncology, vol.46, issue.2, pp.657-66, 2015. ,
DOI : 10.3892/ijo.2014.2763
The basics of epithelial-mesenchymal transition, Journal of Clinical Investigation, vol.119, issue.6, pp.1420-1428, 2009. ,
DOI : 10.1172/JCI39104
Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy, BJU International, vol.5, issue.11c, pp.1131-1137, 2012. ,
DOI : 10.1111/j.1464-410X.2012.11297.x
A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma, Annual Review of Pathology: Mechanisms of Disease, vol.10, issue.1, pp.263-89, 2015. ,
DOI : 10.1146/annurev-pathol-012414-040306
Molecular Genetics of Clear-Cell Renal Cell Carcinoma, Journal of Clinical Oncology, vol.32, issue.18, pp.1968-76, 2014. ,
DOI : 10.1200/JCO.2012.45.2003
Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression, The Journal of Urology, vol.195, issue.1, pp.180-187, 2016. ,
DOI : 10.1016/j.juro.2015.07.113
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation, The Lancet Oncology, vol.14, issue.2, pp.159-67, 2013. ,
DOI : 10.1016/S1470-2045(12)70584-3
Protein Kinase CK2 and Angiogenesis, Advances in Clinical and Experimental Medicine, vol.23, issue.2, pp.153-161, 2014. ,
DOI : 10.17219/acem/37040
CK2 as a positive regulator of Wnt signalling and tumourigenesis, Molecular and Cellular Biochemistry, vol.20, issue.1-2, pp.63-70, 2005. ,
DOI : 10.1007/s11010-005-3078-0
Overlapping kinetochore targets of CK2 and Aurora B kinases in mitotic regulation, Molecular Biology of the Cell, vol.22, issue.15, pp.2680-2689, 2011. ,
DOI : 10.1091/mbc.E10-11-0915
Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo, Nature Immunology, vol.112, issue.3, pp.267-75, 2015. ,
DOI : 10.4049/jimmunol.1004136
CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy, Cancer Research, vol.70, issue.24, pp.10288-98, 2010. ,
DOI : 10.1158/0008-5472.CAN-10-1893